Circulating levels of the Wnt/β-catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in Diabetes Care.
Read more
Sclerostin linked to vascular disease in type 2 diabetes
Posted in Type II Medical Research